Competitive and specific inhibitor of Type II 5a-reductase.
Mechanism:
Turosteride blocks the peripheral conversion of testosterone to DHT by type II 5a-reductase in competitive mode, resulting in significant decreases in serum and tissue DHT concentrations. Turosteride did not show any relevant binding affinity to the androgen receptor.
However, at variance with other 5 alpha-reductase inhibitors (e.g. finasteride), turosteride caused a decrease in prostatic DHT not associated with a secondary increase in T content. This peculiarity of turosteride may represent an improvement of the compound over other inhibitors.
All this make Turosteride a promissing 5alfa-reductase inhibitor.
Specific studies on androgenetic alopecia are not known.
Availability: Prescription. |
|
|
|
